February 01, 2022
Gilead has agreed to pay $1.25 billion plus royalties to GlaxoSmithKline venture ViiV Healthcare to settle claims Gilead infringed patents with its HIV drug, the companies announced Tuesday, a deal that comes less than a month after a trial in the high-profile case was delayed due to COVID-19.
January 05, 2022
The beginning of January was shaping up to be a busy time for patent jury trials with judges scheduling several to kick off the new year, following a lull during the pandemic, but skyrocketing viral infections have led many of the trials to be postponed.
January 04, 2022
Two notable intellectual property trials have been postponed amid the latest COVID-19 surge, with a case against Gilead over HIV drug patents now set to head to trial in May and another claiming Samsung infringed a wireless battery charging patent scheduled to go before a jury next month.
December 16, 2021
Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations Gilead made billions by selling HIV medications using research funded by taxpayers. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.